Lv3
360 积分 2021-12-21 加入
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
1天前
已完结
Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine
1天前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
1天前
已完结
Hypoxia, Psychedelics, and Terminal Lucidity: A Perspective on Neuroplasticity and Neuropsychiatric Disorders
7天前
已完结
YAP/TAZ as master regulators in liver regeneration and disease: insights into mechanisms and therapeutic targets
1个月前
已完结
NAFLD and NASH: etiology, targets and emerging therapies
1个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
1个月前
已完结
Buddleoside alleviates nonalcoholic steatohepatitis by targeting the AMPK-TFEB signaling pathway
1个月前
已完结
Targeting fibrosis and steatosis: Nebivolol multi-pathway modulator ameliorates experimental non-alcoholic steatohepatitis in rats through AMPK/mTOR and TGF-β1/α-SMA pathways
2个月前
已完结
Retrograde mitochondrial signaling governs the identity and maturity of metabolic tissues
4个月前
已完结
皖公网安备34019202002308
